{
  "drug_status": {
    "Autologous Hematopoietic Stem Cell": "success",
    "CD19/CD22 Dual-Target CAR-T": "success"
  },
  "extractions": {
    "Autologous Hematopoietic Stem Cell": {
      "drug_name": "Autologous Hematopoietic Stem Cell",
      "drug_classes": [
        "Autologous Hematopoietic Stem Cell Therapy"
      ],
      "selected_sources": [
        "abstract_title"
      ],
      "confidence_score": 1.0,
      "extraction_details": [
        {
          "extracted_text": "Autologous hematopoietic stem cell",
          "normalized_form": "Autologous Hematopoietic Stem Cell Therapy",
          "class_type": "MoA",
          "evidence": "Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy",
          "source": "abstract_title",
          "rules_applied": [
            "Rule 1: Prioritize abstract title",
            "Rule 3: Apply Title Case",
            "Rule 25: Append 'therapy' to cell type",
            "Rule 32: Do not semantically alter modality"
          ]
        }
      ],
      "extraction_method": "tavily",
      "reasoning": "The abstract title explicitly mentions 'Autologous hematopoietic stem cell transplantation'. Following Rule 25, the cell type 'Autologous hematopoietic stem cell' is converted to therapy format by appending 'therapy'. Rule 1 and Rule 2 prioritize classes found in the abstract title.",
      "success": true
    },
    "CD19/CD22 Dual-Target CAR-T": {
      "drug_name": "CD19/CD22 Dual-Target CAR-T",
      "drug_classes": [
        "CD19/CD22-Targeted CAR-T Cell Therapy"
      ],
      "selected_sources": [
        "abstract_title"
      ],
      "confidence_score": 1.0,
      "extraction_details": [
        {
          "extracted_text": "CD19/CD22 dual-target CAR-T therapy",
          "normalized_form": "CD19/CD22-Targeted CAR-T Cell Therapy",
          "class_type": "MoA",
          "evidence": "Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy for refractory or relapsed burkitt lymphoma",
          "source": "abstract_title",
          "rules_applied": [
            "Rule 1: Prioritize abstract title",
            "Rule 3: Apply Title Case",
            "Rule 10: List targets alphabetically (CD19 before CD22)",
            "Rule 11: Include biological targets in TARGET-Modality format",
            "Rule 25: Append 'therapy' to cell type (CAR-T Cell Therapy)",
            "Rule 29: Use standard nomenclature"
          ]
        }
      ],
      "extraction_method": "tavily",
      "reasoning": "The abstract title explicitly identifies the drug as a 'CD19/CD22 dual-target CAR-T therapy'. Following Rule 1 and Rule 2, the title is the highest priority source. Applying Rule 3 (Title Case), Rule 10 (Alphabetical order of targets), Rule 11 (Target-Modality format), Rule 25 (Appending 'therapy' to cell types), and Rule 29 (Standard nomenclature), the class is normalized to 'CD19/CD22-Targeted CAR-T Cell Therapy'.",
      "success": true
    }
  }
}